Akari Therapeutics, Plc (CLA.F)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Abizer Gaslightwala | CEO, President & Director | 1.6k | -- | 1974 |
Dr. Torsten Hombeck Ph.D. | Chief Financial Officer | 259.07k | -- | 1970 |
Dr. Miles Nunn | Chief Scientific Officer | -- | -- | 1970 |
Dr. Satyajit Mitra Ph.D. | Executive Director & Head of Oncology | -- | -- | 1975 |
Mr. Mark F. Kubik M.B.A. | Head of Business Development - Oncology | -- | -- | 1965 |
Akari Therapeutics, Plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
May 13, 2025 at 8:00 PM UTC - May 28, 2025 at 8:00 PM UTC
Akari Therapeutics, Plc Earnings Date
Recent Events
Recent Events Information Not Available